Adage Capital Partners Gp, L.L.C. Amarin Corp Plcuk Transaction History

Adage Capital Partners Gp, L.L.C.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 15, 2020	SELL	$4.0 - $21.53 $8 Million - $43.1 Million	-2,000,000 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$13.94 - $24.12 $35.9 Million - $62.1 Million	-2,575,000 Reduced 56.28%	2,000,000 $42.9 Million
Q3 2019 Nov 14, 2019	BUY	$13.89 - $23.16 $16.7 Million - $27.8 Million	1,200,000 Added 35.56%	4,575,000 $69.4 Million
Q2 2019 Aug 14, 2019	BUY	$16.27 - $20.51 $14.6 Million - $18.5 Million	900,000 Added 36.36%	3,375,000 $65.4 Million
Q1 2019 May 15, 2019	BUY	$12.61 - $22.33 $6.31 Million - $11.2 Million	500,000 Added 25.32%	2,475,000 $51.4 Million
Q4 2018 Feb 14, 2019	SELL	$12.41 - $22.98 $18.9 Million - $35 Million	-1,525,000 Reduced 43.57%	1,975,000 $26.9 Million
Q3 2018 Nov 14, 2018	SELL	$2.45 - $16.27 $3.06 Million - $20.3 Million	-1,250,000 Reduced 26.32%	3,500,000 $56.9 Million
Q2 2018 Aug 14, 2018	BUY	$2.68 - $3.48 $2.01 Million - $2.61 Million	750,000 Added 18.75%	4,750,000 $14.7 Million
Q4 2017 Feb 14, 2018	BUY	$3.06 - $4.09 $9.18 Million - $12.3 Million	3,000,000 Added 300.0%	4,000,000 $16 Million
Q3 2017 Nov 14, 2017	BUY	$3.03 - $3.72 $3.03 Million - $3.72 Million	1,000,000	1,000,000 $3.5 Million

182

71.1M

183K

66.7K

Ticker AMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 403,206,016
Market Cap $230M
Description
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for r...

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.